文献速递心境障碍

第二代抗抑郁药联合心境稳定剂或不典型抗精神病药治疗急性双相抑郁的安全性与疗效

Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials.
PubMed 文献 · Lancet Psychiatry · 2016-10-26

该系统综述与荟萃分析纳入6项随机双盲安慰剂对照试验共1383例急性双相抑郁患者,评估第二代抗抑郁药联合心境稳定剂或不典型抗精神病药的疗效与安全性。结果显示联合治疗在临床评定的抑郁症状评分上有小幅度但显著的改善,但临床应答率和缓解率与安慰剂无显著差异;急性治疗未增加转躁风险,但52周扩展期转躁风险增加。

要点

  • 联合第二代抗抑郁药仅小幅改善抑郁症状评分,未提高临床应答或缓解率。
  • 急性期治疗不增加转躁风险,但长期(52周)使用与转躁风险增加相关。
  • 建议仅短期使用第二代抗抑郁药联合治疗急性双相抑郁。

核心结论

  • 联合第二代抗抑郁药可小幅减轻急性双相抑郁症状,但未增加临床应答或缓解率。
  • 长期使用与治疗引发的躁狂或轻躁狂风险增加相关,应仅限短期使用。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane Central Register of Controlled Trials和ClinicalTrials.gov从建库至2016年1月31日。
  • 纳入6项随机双盲安慰剂对照试验,共1383例急性双相抑郁患者,评估第二代抗抑郁药联合心境稳定剂或不典型抗精神病药。
  • 主要结局为临床医生评定的抑郁症状评分变化,次要结局包括临床应答、临床缓解、治疗引发的躁狂或轻躁狂及耐受性。

临床怎么用

  • 第二代抗抑郁药联合心境稳定剂或不典型抗精神病药可用于急性双相抑郁的短期症状改善。
  • 因长期使用增加转躁风险,应避免长期联合治疗,仅限短期应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although mania and hypomania define bipolar disorder, depressive episodes are more common and impairing, with few proven treatments. Adjunctive therapy with second-generation antidepressants is widely used to treat acute bipolar depression, but their efficacy and safety remain controversial. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception to Jan 31, 2016, for randomised, double-blind, placebo-controlled trials of second-generation antidepressants adjunctive to a mood stabiliser or an antipsychotic in patients with acute bipolar depression. We extracted data from published reports. The primary outcome was change in clinician-rated depressive symptom score; secondary outcomes were clinical response, clinical remission, treatment-emergent mania or hypomania, and tolerability (using dropout rates as a proxy). We used pooled random-effects models, subgroup comparisons, and meta-regression for analyses. We made subgroup comparisons on the basis of mood stabiliser or antipsychotic treatment and did meta-regression examining trial duration. This study is registered with PROSPERO, number CRD#42015016024. FINDINGS: We identified six trials representing 1383 patients with bipolar depression. Second-generation antidepressants were associated with a small but significant improvement in clinician-rated depressive symptom score (standardised mean differences 0·165 [95% CI 0·051-0·278], p=0·004). However, clinical response and remission rates did not differ significantly between patients receiving adjunctive antidepressants and those receiving placebo (1·158 [0·840-1·597], p=0·371 for clinical response; 1·220 [0·874-1·703], p=0·243 for remission). Acute treatment was not associated with an increased risk of treatment-emergent mania or hypomania (0·926 [0·576-1·491], p=0·753), but 52 week extension periods were associated with an increase in risk (1·774 [1·018-3·091], p=0·043). INTERPRETATION: Adjunctive second-generation antidepressants are associated with reduced symptoms of acute bipolar depression, but the magnitude of benefit is small because they do not increase clinical response or remission rates. However, these medications should be used only in the short term because prolonged use is associated with an increased risk of treatment-emergent mania or hypomania. FUNDING: None.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. McGirr A, Vöhringer PA, Ghaemi SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016. PMID: 28100425. doi:10.1016/S2215-0366(16)30264-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。